Research Studies: Multiple System Atrophy

Currently Enrolling Studies

A Randomized Double-Blind, Placebo-Controlled Study of ATH434-201 to determine efficacy, safety and tolerability in patients with MSA (2)

• To assess the efficacy of the study drug (ATH434) in patients with MSA
• To assess whether the study drug (ATH434) is save and tolerable in patients with MSA
• Currently enrolling adults aged 30 to 75 with a confirmed diagnosis of MSA

CYPRESS: A Phase 3, Multi-center, Randomized Withdrawal and Long-Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants with Multiple System Atrophy 

• To evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic Neurogenic orthostatic hypotension (dizziness, feeling light-headed, feeling faint, feeling like blacking out)  compared with placebo
•  This study is currently recruiting participants over the age of 30 with MSA

Ongoing Studies Currently Closed to Enrollment

AMULET: Interventional, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Lu AF82122 in Patients with Multiple System Atrophy (MSA)

• The study is testing a drug called Lu AF82422 to evaluate its efficacy on disease progression in patients with Multiple System Atrophy (MSA).
• Autonomic symptoms should have been present for no more than 5 years at time of screening
• Between ages of 40 and 75

For any questions please contact our research manager, Ileana Rubio at (858) 246-2505 or irubio@health.ucsd.edu.